Hemoconcentration and predictors in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS).
Children
EHEC
HUS
Hemoconcentration
Outcome
Predictors
STEC
Journal
Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
12
01
2021
accepted:
28
04
2021
revised:
18
04
2021
pubmed:
29
5
2021
medline:
26
3
2022
entrez:
28
5
2021
Statut:
ppublish
Résumé
Hemoconcentration has been identified as a risk factor for a complicated course in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). This single-center study assesses hemoconcentration and predictors at presentation in STEC-HUS treated from 2009-2017. Data of 107 pediatric patients with STEC-HUS were analyzed retrospectively. Patients with mild HUS (mHUS, definition: max. serum creatinine < 1.5 mg/dL and no major neurological symptoms) were compared to patients with severe HUS (sHUS, definition: max. serum creatinine ≥ 1.5 mg/dL ± major neurological symptoms). Additionally, predictors of complicated HUS (dialysis ± major neurological symptoms) were analyzed. Sixteen of one hundred seven (15%) patients had mHUS. Admission of patients with sHUS occurred median 2 days earlier after the onset of symptoms than in patients with mHUS. On admission, patients with subsequent sHUS had significantly higher median hemoglobin (9.5 g/dL (3.6-15.7) vs. 8.5 g/dL (4.2-11.5), p = 0.016) than patients with mHUS. The product of hemoglobin (g/dL) and LDH (U/L) (cutoff value 13,302, sensitivity 78.0%, specificity of 87.5%) was a predictor of severe vs. mild HUS. Creatinine (AUC 0.86, 95% CI 0.79-0.93) and the previously published score hemoglobin (g/dL) + 2 × creatinine (mg/dL) showed a good prediction for development of complicated HUS (AUC 0.87, 95% CI 0.80-0.93). At presentation, patients with subsequent severe STEC-HUS had a higher degree of hemoconcentration. This underlines that fluid loss or reduced fluid intake/administration may be a risk factor for severe HUS. The good predictive value of the score hemoglobin (g/dL) + 2 × creatinine (mg/dL) for complicated HUS could be validated in our cohort. A higher resolution version of the Graphical abstract is available as Supplementary Information.
Sections du résumé
BACKGROUND
Hemoconcentration has been identified as a risk factor for a complicated course in Shiga toxin-producing E. coli-hemolytic uremic syndrome (STEC-HUS). This single-center study assesses hemoconcentration and predictors at presentation in STEC-HUS treated from 2009-2017.
METHODS
Data of 107 pediatric patients with STEC-HUS were analyzed retrospectively. Patients with mild HUS (mHUS, definition: max. serum creatinine < 1.5 mg/dL and no major neurological symptoms) were compared to patients with severe HUS (sHUS, definition: max. serum creatinine ≥ 1.5 mg/dL ± major neurological symptoms). Additionally, predictors of complicated HUS (dialysis ± major neurological symptoms) were analyzed.
RESULTS
Sixteen of one hundred seven (15%) patients had mHUS. Admission of patients with sHUS occurred median 2 days earlier after the onset of symptoms than in patients with mHUS. On admission, patients with subsequent sHUS had significantly higher median hemoglobin (9.5 g/dL (3.6-15.7) vs. 8.5 g/dL (4.2-11.5), p = 0.016) than patients with mHUS. The product of hemoglobin (g/dL) and LDH (U/L) (cutoff value 13,302, sensitivity 78.0%, specificity of 87.5%) was a predictor of severe vs. mild HUS. Creatinine (AUC 0.86, 95% CI 0.79-0.93) and the previously published score hemoglobin (g/dL) + 2 × creatinine (mg/dL) showed a good prediction for development of complicated HUS (AUC 0.87, 95% CI 0.80-0.93).
CONCLUSIONS
At presentation, patients with subsequent severe STEC-HUS had a higher degree of hemoconcentration. This underlines that fluid loss or reduced fluid intake/administration may be a risk factor for severe HUS. The good predictive value of the score hemoglobin (g/dL) + 2 × creatinine (mg/dL) for complicated HUS could be validated in our cohort. A higher resolution version of the Graphical abstract is available as Supplementary Information.
Identifiants
pubmed: 34046736
doi: 10.1007/s00467-021-05108-6
pii: 10.1007/s00467-021-05108-6
pmc: PMC8497454
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3777-3783Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021. The Author(s).
Références
Pediatr Int. 1999 Apr;41(2):223-7
pubmed: 10221034
Clin Infect Dis. 2012 Sep;55(6):753-9
pubmed: 22670043
Pediatr Nephrol. 2020 Feb;35(2):331-339
pubmed: 31475299
Presse Med. 2012 Mar;41(3 Pt 2):e115-35
pubmed: 22284541
Pediatrics. 2006 May;117(5):1656-62
pubmed: 16651320
Clin Infect Dis. 2017 Jun 15;64(12):1637-1643
pubmed: 28329394
Pediatrics. 2016 Jan;137(1):
pubmed: 26644486
Arch Pediatr Adolesc Med. 2011 Oct;165(10):884-9
pubmed: 21784993
Pediatr Nephrol. 2015 Feb;30(2):345-52
pubmed: 25149851
Lancet. 2005 Mar 19-25;365(9464):1073-86
pubmed: 15781103
N Engl J Med. 2002 Jan 3;346(1):23-32
pubmed: 11777999
JAMA Pediatr. 2017 Jan 1;171(1):68-76
pubmed: 27893870
Eur J Pediatr. 2018 Nov;177(11):1667-1674
pubmed: 30094644
Pediatr Nephrol. 2021 Jan;36(1):103-109
pubmed: 32681274
Pediatr Infect Dis J. 2000 Jul;19(7):642-7
pubmed: 10917223
Pediatr Int. 2009 Apr;51(2):216-9
pubmed: 19405919
Pediatr Nephrol. 2018 Oct;33(10):1791-1798
pubmed: 29961127
J Intern Med. 2017 Feb;281(2):123-148
pubmed: 27723152
Pediatr Nephrol. 2018 Nov;33(11):2057-2071
pubmed: 29372302
J Pediatr. 2015 Apr;166(4):1022-9
pubmed: 25661408
Eur J Intern Med. 2014 Feb;25(2):e29
pubmed: 24360866
Pediatr Nephrol. 2012 Aug;27(8):1407-10
pubmed: 22476204
Clin Infect Dis. 2020 Apr 10;70(8):1643-1651
pubmed: 31125419
Pediatr Nephrol. 2015 Dec;30(12):2115-9
pubmed: 26141929
Pediatrics. 2005 Jun;115(6):e673-80
pubmed: 15930195
J Pediatr. 2021 May;232:200-206.e4
pubmed: 33417918
Clin Infect Dis. 2012 Jul;55(1):33-41
pubmed: 22431799
Clin Infect Dis. 2012 May;54(10):1413-21
pubmed: 22412065